All In Biotech

Drug Trial Radar · NCT00106288

Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia

A Multicenter, Double Blind, Comparative, Randomized Study to Evaluate the Efficacy and Safety of Micafungin (FK463) Versus Liposomal Amphotericin B (AmBisome) in the Treatment of Invasive Candidiasis and Candidemia

Last checked: Nov 19, 2026Latest source record: Sep 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 637 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

637

Actual

Start

Jan 2003

Primary completion

Dec 2005

Study completion Dec 2005

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Mar 23, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy and safety of micafungin (FK463) versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic patients with confirmed invasive candidiasis or candidemia. Enrollment will include adult and pediatric patients.

Conditions

  • Candidiasis

Interventions

  • MicafunginDrug

    IV

  • Liposomal Amphotericin BDrug

    IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator's assessment of overall treatment success. Success is defined as clinical (complete or partial) and mycological (eradication or presumed eradication) response at the End of Therapy.Time frame: 6 and 12 weeks post treatment

Locations

37 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Orange, California

  • Site not named

    Denver, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Jacksonville, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Hinsdale, Illinois

  • Site not named

    Maywood, Illinois

  • Site not named

    Kansas City, Kansas

  • Site not named

    Lexington, Kentucky

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    Rochester, New York

  • Site not named

    Valhalla, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Houston, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Provo, Utah

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Winnipeg, Manitoba, Canada

  • Site not named

    Halifax, Nova Scotia, Canada

  • Site not named

    Hamilton, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Québec, Quebec, Canada

  • Site not named

    Regina, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.